Evaluating the Safety and Pharmacokinetics of ABT-414 for Subjects With Glioblastoma Multiforme

PHASE1CompletedINTERVENTIONAL

Enrollment

202

Participants

Timeline

Start Date

April 2, 2013

Primary Completion Date

June 19, 2017

Study Completion Date

June 19, 2017

Conditions

Glioblastoma Multiforme

Interventions

DRUG

ABT-414

ABT-414 will be administered by intravenous infusion

DRUG

Temozolomide

Temozolomide will be administered per label and local prescribing regulations.

RADIATION

Whole Brain Radiation

Whole Brain radiation will be administered in 30 fractions.